BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 29772250)

  • 1. Development and validation of a novel semi-homogenous clinical assay for quantitation of Ranibizumab in human serum.
    Lowe J; Wakshull E; Shek T; Chuntharapai A; Elliott R; Rusit J; Maia M
    J Immunol Methods; 2018 Oct; 461():44-52. PubMed ID: 29772250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a novel homogenous electrochemiluminescence assay for quantitation of ranibizumab in human serum.
    Lowe J; Maia M; Wakshull E; Siguenza P; Liu P; Lakhani S; Rusit J; Elliott R; Quarmby V
    J Pharm Biomed Anal; 2010 Sep; 52(5):680-6. PubMed ID: 20226615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular Endothelial Growth Factor (VEGF) Concentration Is Underestimated by Enzyme-Linked Immunosorbent Assay in the Presence of Anti-VEGF Drugs.
    Takahashi H; Nomura Y; Nishida J; Fujino Y; Yanagi Y; Kawashima H
    Invest Ophthalmol Vis Sci; 2016 Feb; 57(2):462-6. PubMed ID: 26868748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits.
    Gaudreault J; Fei D; Beyer JC; Ryan A; Rangell L; Shiu V; Damico LA
    Retina; 2007; 27(9):1260-6. PubMed ID: 18046235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Mechanistic Model of the Intravitreal Pharmacokinetics of Large Molecules and the Pharmacodynamic Suppression of Ocular Vascular Endothelial Growth Factor Levels by Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration.
    Hutton-Smith LA; Gaffney EA; Byrne HM; Maini PK; Schwab D; Mazer NA
    Mol Pharm; 2016 Sep; 13(9):2941-50. PubMed ID: 26726925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Production of monoclonal antibodies for measuring Avastin and its biosimilar by Sandwich ELISA.
    Li M; An W; Wang L; Zhang F; Li J; Zhang Y; Li Y; Li H; Ren W; Zhao R; Xia C; Sun L
    J Immunol Methods; 2019 Jun; 469():42-46. PubMed ID: 30943379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.
    Avery RL; Castellarin AA; Steinle NC; Dhoot DS; Pieramici DJ; See R; Couvillion S; Nasir MA; Rabena MD; Maia M; Van Everen S; Le K; Hanley WD
    Retina; 2017 Oct; 37(10):1847-1858. PubMed ID: 28106709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histological and Immunohistochemical Retinal Changes Following the Intravitreal Injection of Aflibercept, Bevacizumab and Ranibizumab in Newborn Rabbits.
    Cam D; Berk AT; Micili SC; Kume T; Ergur BU; Yilmaz O
    Curr Eye Res; 2017 Feb; 42(2):315-322. PubMed ID: 27314606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
    Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF
    Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Critical role of bioanalytical strategies in investigation of clinical PK observations, a Phase I case study.
    Peng K; Xu K; Liu L; Hendricks R; Delarosa R; Erickson R; Budha N; Leabman M; Song A; Kaur S; Fischer SK
    MAbs; 2014; 6(6):1500-8. PubMed ID: 25484037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomab.
    Siebert N; Seidel D; Eger C; Brackrock D; Reker D; Schmidt M; Lode HN
    J Immunol Methods; 2013 Dec; 398-399():51-9. PubMed ID: 24055592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic counterregulatory response of placental growth factor levels to intravitreal aflibercept therapy.
    Zehetner C; Bechrakis NE; Stattin M; Kirchmair R; Ulmer H; Kralinger MT; Kieselbach GF
    Invest Ophthalmol Vis Sci; 2015 May; 56(5):3279-86. PubMed ID: 26024110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization and method validation for the quantitative analysis of a monoclonal antibody and its related fab fragment in human plasma after intravitreal administration, using LC-MS/MS.
    DelGuidice CE; Ismaiel OA; Mylott WR; Halquist MS
    J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Feb; 1164():122474. PubMed ID: 33508760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
    Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
    Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-VEGF drug interference with VEGF quantitation in the R&D systems human quantikine VEGF ELISA kit.
    Sumner G; Georgaros C; Rafique A; DiCioccio T; Martin J; Papadopoulos N; Daly T; Torri A
    Bioanalysis; 2019 Mar; 11(5):381-392. PubMed ID: 30892063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of an immunoassay for human-specific quantitation of therapeutic antibodies in serum samples from non-human primates.
    Stubenrauch K; Wessels U; Lenz H
    J Pharm Biomed Anal; 2009 May; 49(4):1003-8. PubMed ID: 19250787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of murine anti-human Fab antibodies for use in an immunoassay for generic quantification of human Fab fragments in non-human serum samples including cynomolgus monkey samples.
    Stubenrauch K; Wessels U; Essig U; Kowalewsky F; Vogel R; Heinrich J
    J Pharm Biomed Anal; 2013 Jan; 72():208-15. PubMed ID: 23017233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Theoretical Insights into the Retinal Dynamics of Vascular Endothelial Growth Factor in Patients Treated with Ranibizumab, Based on an Ocular Pharmacokinetic/Pharmacodynamic Model.
    Hutton-Smith LA; Gaffney EA; Byrne HM; Caruso A; Maini PK; Mazer NA
    Mol Pharm; 2018 Jul; 15(7):2770-2784. PubMed ID: 29734810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intact quantitative bioanalytical method development and fit-for-purpose validation of a monoclonal antibody and its related fab fragment in human vitreous and aqueous humor using LC-HRMS.
    DelGuidice CE; Ismaiel OA; Mylott WR; Yuan M; Halquist MS
    Anal Bioanal Chem; 2022 Jun; 414(14):4189-4202. PubMed ID: 35451621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SERUM LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR BEFORE AND AFTER INTRAVITREAL INJECTION OF RANIBIZUMAB OR CONBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Jin E; Bai Y; Luo L; Huang L; Zhu X; Ding X; Qi H; Zhao M
    Retina; 2017 May; 37(5):971-977. PubMed ID: 27617537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.